摘要
目的通过临床实验观察采用胸痹通胶囊联合常规西药治疗慢性心力衰竭病人的临床疗效,评价胸痹通胶囊对慢性心力衰竭的治疗效果。方法选择慢性心力衰竭患者60例,将其随机分为实验组和对照组,每组30例。实验组予以胸痹通胶囊口服,并予以常规西药配合治疗。对照组30例,只进行常规西药治疗。疗程均为30d,观察并记录治疗前后两组患者血清N末端脑钠肽前体(NT-ProBNP)及肌钙蛋白Ⅰ(CTnⅠ)的浓度变化。结果实验组能够显著降低血清NT-ProBNP及CTnⅠ含量,其疗效与对照组比较,差异有显著性(P<0.05)。结论胸痹通胶囊能够显著降低血清中NT-ProBNP和CTnⅠ水平,并显著提高治疗效果。
Objective To observe the clinical effect of Xiongbitong capsule combined with conventional western medicine in the treatment of chronic heart failure by clinical experiment,and to evaluate the therapeutic effect of Xiongbitong capsule on chronic heart failure.Methods Selection of patients with chronic heart failure in 60 cases,60 patients were randomly divided into experimental group 30 cases,be Xiongbitong capsule orally,at the same time to conventional western medicine with the treatment.A control group of 30 cases,to be applied individually to conventional western medicine.Two groups were treated for 30 days.Two groups of patients were observed and the concentration changes of NT-pro BNP and CTnⅠ record before and after treatment.Results The experimental group can reduce the NT-pro BNP,reduce the CTnⅠ,and its clinical efficacy and the control group with significant difference.Conclusion Xiongbitong capsule can decrease the concentration of NT-ProBNP and CTnⅠin serum.
出处
《潍坊医学院学报》
2017年第3期191-192,共2页
Acta Academiae Medicinae Weifang
